Quick Answer
Biofrontera Inc. reported Stockholders Equity of $10.48 million for the year ending 2025.
- Biofrontera Inc. showed an increase of +136.4% in Stockholders Equity from 2024 to 2025.
- This data is from Biofrontera Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$38.00 million | Q3 2020: -$40.98 million | Q1 2021: $2.29 million | Q2 2021: -$1.37 million | Q3 2021: -$17.38 million | Q1 2022: $17.42 million | Q2 2022: $17.23 million | Q3 2022: $22.60 million | Q1 2023: $16.75 million | Q2 2023: $7.17 million | Q3 2023: $1.04 million | Q1 2024: -$5.42 million | Q2 2024: $10.91 million | Q3 2024: $5.53 million | Q1 2025: $500.0 thousand | Q2 2025: -$4.67 million | Q3 2025: -$2.58 million.
- Over the full 7 years of available data (2019 to 2025), Biofrontera Inc.'s Stockholders Equity has grown by 134.7%.
- Historical annual values: Fiscal year 2025: $10.48 million | Fiscal year 2024: $4.43 million | Fiscal year 2023: $4.79 million | Fiscal year 2022: $23.88 million | Fiscal year 2021: $11.34 million | Fiscal year 2020: $5.83 million | Fiscal year 2019: -$30.18 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: